

Dear Valued Investigator:

We are pleased to share that effective July 12, 2011, INC Research has acquired Kendle and the combined organization will operate under the INC Research name. This combination of top CROs is an exceptional fit. With approximately 5,000 employees across six continents and experience spanning more than 100 countries, we are truly one of the elite companies in the CRO marketplace.

INC Research is positioned to compete for clinical trials of any size and scope and will offer expanded opportunities to our investigative site partners. We recognize the critical role you will continue to play in our success and look forward to a productive association with you in support of our customers' drug development programs.

Our highest priority during integration remains the successful execution and delivery of clinical trials for our customers. Therefore, ongoing projects will be unaffected by this acquisition and you will continue to work with the same highly-skilled teams currently assigned to your trials.

To ensure that we are able to continue to work with you, we ask that you:

- Visit the INC Research investigator database registration page, accessible at [www.incresearch.com](http://www.incresearch.com) by clicking "Investigators" or by linking directly [here](#), to register in the INC Research database and complete the privacy policy/consent.
- Update, if necessary, your profile in the Kendle database. The Kendle database may be accessed by following the "For Investigators" link at [www.kendle.com](http://www.kendle.com) or by linking directly to the database [here](#).

Over time these databases will be consolidated into a single resource. To ensure we do not miss any opportunities to work with you during the integration, we request that you submit your information to the INC Research system and update your profile with Kendle.

If you have any questions about the acquisition, we invite you to visit our website to review the [press release](#) or contact us directly at [feasibility@incresearch.com](mailto:feasibility@incresearch.com). We look forward to working with you in the future.

Best regards,

A handwritten signature in black ink, appearing to read 'Chantal Demblon'.

Chantal Demblon  
Director, Study Start-Up